Biotech Companies Express Concern With Proposed Changes to the Medicaid Drug Rebate Program (MDRP)
April 11, 2024
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry and create extensive barriers to patient access to existing innovative therapies and to developing new cures for Medicaid enrollees.1 As a result, it will deny some of the nation's most vulnerable patients access to the state-of-the-art medical care they deserve, both now and in the future.
Download Full Comments Below
Biotech Companies Express Concern With Proposed changes to the Medicaid Drug Rebate Program
Dear Majority Leader Thune, Minority Leader Schumer, Speaker Johnson, and Minority Leader Jeffries:The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory based non-profit trade associations, each of…
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry and create extensive barriers to patient access to existing innovative therapies and to developing new cures for Medicaid enrollees.1 As a result, it will deny some of the nation's most vulnerable patients access to the state-of-the-art medical care they deserve, both now and in the future.